

In the Claims:

1. (Original) A conjugate comprising (a) an amphiphilic transport peptide of human origin as a transmembrane module (~~TPU~~), (b) a nuclear localization sequence (~~NLS~~), wherein said nuclear localization sequence is covalently coupled to the transmembrane module via a cleavable spacer, and (c) a signalling and/or drug carrying module (~~SM~~).
2. . (Currently Amended) The conjugate of claim 1, wherein the signalling and/or drug carrying module comprises Gd, Ga, Mn, I, Fe and/or F as (~~diagnostic~~) image creating compound.
3. (Currently Amended) The conjugate of claim 1 or ~~2~~, wherein the transmembrane module (~~TPU~~) is the human homeobox protein HOX-B1 or derivative thereof having an amino acid sequence identity to HOX-B1 of at least 60%.
4. . (Currently Amended) The conjugate of claim 3, wherein the transmembrane module (~~TPU~~) comprises the amino acid sequence TQVKIWFQNRRMKQKK.
5. (Currently Amended) The conjugate according to ~~any one of claims 1 to 4~~ claim 1, wherein the nuclear localization sequence (~~NLS~~) comprises the amino acid sequence PKKKRKV or KPKRVKK.
6. (Currently Amended) The conjugate according to ~~any one of claims 1 to 5~~ claim 1, wherein the nuclear localization sequence (~~NLS~~) is coupled to the signalling and/or drug carrying module (~~SM~~) or a compound trapping the signalling and/or drug carrying module (~~SM~~) via a non-cleavable spacer II.
7. (Original) The conjugate according to claim 6, wherein spacer I comprises a cleavable disulfide bridge.

8. . (Currently Amended) The conjugate according to claim [[7]] 6, wherein spacer II is polylysine.

9. . (Currently Amended) The conjugate according to ~~any one of claims 6 to 8~~ claim 6, wherein spacer II carries an FITC label.

10. . (Currently Amended) The conjugate according to ~~any one of claims 1 to 9~~ claim 1, wherein the conjugate has the following structure: transmembrane module (TPU) - spacer I – nuclear localization sequence (NLS) - spacer II - signalling and/or drug carrying module (SM) or compound trapping the signalling and/or drug carrying module + signalling and/or drug carrying module (SM).

11. . (Currently Amended) The conjugate of ~~any one of claims 1 to 10~~ claim 1, wherein said conjugate further comprises a cytotoxic drug.

12. . (Currently Amended) Use of the conjugate of ~~any one of claims 1 to 10~~ claim 1 for the preparation of a diagnostic composition for cell tracking.

13. (Currently Amended) Use of the conjugate of ~~any one of claims 1 to 10~~ claim 1 for the preparation of a contrast agent for MRI.

14. (Currently Amended) Use of the conjugate of ~~any one of claims 1 to 10~~ claim 1 for the preparation of a diagnostic composition for determining the activity of DNA repair enzymes.

15. (Currently Amended) Use of the conjugate of ~~any one of claims 1 to 11~~ claim 1 for the preparation of a pharmaceutical composition for the chemotherapeutical treatment of a tumor.

16. (Currently Amended) Use of the conjugate of ~~any one of claims 1 to 11~~ claim 1 for the preparation of a pharmaceutical composition for the intranuclear GNCT-treatment of a tumor.